natgillin/translations-raw huggingface dataset:
In patients treated for haematological malignancies, B cell recovery began within 6 months of treatment and generally returned to normal levels within 12 months after completion of therapy, although in some patients this may take longer (up to a median recovery time of 23 months post-induction therapy). 
Pri bolnikih, ki so se zdravili zaradi hematoloških malignih bolezni, so se celice B začele obnavljati v 6 mesecih zdravljenja, njihovo število pa se je v splošnem vrnilo v normalno stanje v
Hyperglycaemia, weight decrease, peripheral oedema, face oedema, increased LDH, hypocalcaemia 
Presnovne in prehranske motnje hiperglikemij a, zmanjšanje telesne mase, periferni edem, edem obraza, zvišanje LDH, hipokalciemij a
Rixathon 100 mg concentrate for solution for infusion Rixathon 500 mg concentrate for solution for infusion 
Rixathon 100 mg koncentrat za raztopino za infundiranje Rixathon 500 mg koncentrat za raztopino za infundiranje
The recommended dose of Rixathon used as a maintenance treatment for patients with relapsed/refractory follicular lymphoma who have responded to induction treatment is: 375 mg/m2 body surface area once every 3 months (starting 3 months after the last dose of induction therapy) until disease progression or for a maximum period of two years (8 infusions in total). 
Priporočeni odmerek zdravila Rixathon za vzdrževalno zdravljenje bolnikov s ponovitvijo folikularnih limfomov ali neodzivno boleznijo, ki so se odzvali na indukcijsko zdravljenje, je: 375 mg/m2 telesne površine enkrat na 3 mesece (z začetkom 3 mesece po zadnjem odmerku indukcijskega zdravljenja) do napredovanja bolezni ali največ dve leti (skupaj 8 infuzij).
ANNEX II A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z
The reactions reported were usually reversible with a reduction in rate, or interruption, of rituximab infusion and administration of an anti-pyretic, an antihistamine, and, occasionally, oxygen, intravenous saline or bronchodilators, and glucocorticoids if required. 
Reakcije, o katerih so poročali, so bile običajno reverzibilne z zmanjšanjem hitrosti ali prekinitvijo infuzije rituksimaba in dajanjem antipiretika, antihistaminika in občasno kisika,
The most common infections in the rituximab group were herpes simplex and zoster infections, bronchitis, urinary tract infection, fungal infection and conjunctivitis. 
Najpogostejše okužbe v skupini z rituksimabom so bile okužbe z virusoma herpes simpleks in herpes zoster, bronhitis, okužbe sečil,
Duration of response* Disease free survival (DFS)** Time to new treatment 
trajanje odgovora* preživetje brez bolezni**
Patient subpopulations - rituximab monotherapy 
Podskupine bolnikov - samostojno zdravljenje z rituksimabom
collapse 
Dihala
This is a type of protein called a “monoclonal antibody”. 
Zdravilo Rixathon vsebuje učinkovino rituksimab, ki je vrsta beljakovine, imenovana monoklonsko protitelo.
The ADRs listed in Table 3 were all adverse events which occurred at an incidence of ≥ 5% in the rituximab group and at a higher frequency than the comparator group. 
Neželeni učinki, navedeni v preglednici 3, so se v skupini, ki je prejemala rituksimab, pojavili z incidenco ≥ 5 % in pogosteje kot v primerjalni skupini.
Based on a population pharmacokinetic analysis in 298 NHL patients who received single or multiple infusions of rituximab as a single agent or in combination with CHOP therapy (applied rituximab doses ranged from 100 to 500 mg/m2), the typical population estimates of nonspecific clearance (CL1), specific clearance (CL2) likely contributed by B cells or tumour burden, and central compartment volume of distribution (V1) were 0.14 L/day, 0.59 L/day, and 2.7 L, respectively. 
Iz populacijske farmakokinetične analize pri 298 bolnikih z ne-Hodgkinovim limfomom, ki so prejeli enkratno ali večkratno infuzijo rituksimaba (odmerki od 100 do 500 mg/m2) samostojno ali v kombinaciji s CHOP, lahko ocenimo nespecifični očistek tipične populacije bolnikov (Cl1): 0,14 l/dan,
Rituximab binds specifically to the transmembrane antigen, CD20, a non-glycosylated phosphoprotein, located on pre-B and mature B lymphocytes. 
Rituksimab se veže specifično na transmembranski antigen, CD20, neglikoziliran fosfoprotein, ki se nahaja na limfocitih pre-B in dozorelih limfocitih B. Antigen je izražen pri > 95 % vseh B-celičnih ne-Hodgkinovih limfomov.
In patients with non-Hodgkin's lymphoma and chronic lymphocytic leukaemia, premedication with glucocorticoids should be considered if Rixathon is not given in combination with glucocorticoid-containing chemotherapy. 
Če zdravilo Rixathon za zdravljenje ne-Hodgkinovega limfoma in kronične limfocitne levkemije ni uporabljeno v kombinaciji s kemoterapijo, ki vključuje glukokortikoid, je treba razmisliti o premedikaciji z glukokortikoidi.
In the maintenance therapy clinical trial, 7/57 (12%) patients in the rituximab arm experienced at least one infusion-related reaction. 
V kliničnem preskušanju vzdrževalnega zdravljenja se je vsaj ena z infuzijo povezana reakcija pojavila pri 7 od 57 (12 %) bolnikov v skupini z rituksimabom.
• unusual feelings of the skin - such as numbness, tingling, pricking, burning, a creeping skin feeling, reduced sense of touch 
• neobičajni občutki na koži - na primer omrtvičenost, mravljinčenje, zbadanje, pekoč občutek,
• tightening of the muscles in the airways which causes wheezing (bronchospasm), inflammation, irritation in the lungs, throat or sinuses, being short of breath, runny nose 
• skrčenje mišic v dihalih, ki povzroči piskajoče dihanje (bronhospazem), vnetje, draženje pljuč,
Sepsis, +pneumonia, +febrile infection, +herpes zoster, +respiratory tract infection, fungal infections, infections of unknown aetiology, +acute bronchitis, +sinusitis, hepatitis B1 
glivične okužbe, okužbe neznane etiologije, +akutni bronhitis, +sinuzitis, hepatitis B1
A total of 1,078 patients responded to induction therapy, of which 1,018 were randomised to rituximab maintenance therapy (n=505) or observation (n=513). 
Na indukcijsko zdravljenje se je odzvalo 1.078 bolnikov, od teh jih je bilo 1.018 randomiziranih v vzdrževalno zdravljenje z rituksimabom
The HCP educational leaflet about Rixathon for non-oncology indications contains the following key elements: - The need for close supervision during administration in an environment where full resuscitation facilities are immediately available - The need to check, prior to Rixathon treatment, for infections, for immunosuppression, for prior/current medication affecting the immune system, and recent history of, or planned, vaccination, and a history of infusion-related reaction - The need to monitor patients for infections, especially PML, during and after Rixathon treatment - Detailed information on the risk of PML, the need for timely diagnosis of PML and appropriate measures to diagnose PML - The need to advise patients on the risk of infections and PML, including the symptoms to be aware of and the need to contact their doctor immediately if they experience any. 
- informacije o nujnosti skrbnega nadzora med aplikacijo v okolju, kjer so vsi pripomočki za oživljanje nemudoma na voljo, - informacije o nujnosti, da pred dajanjem zdravila Rixathon preverijo, ali je bolnik morda okužen, imunsko oslabljen, ali jemlje zdravila, ki vplivajo na imunski sistem, ali jih je jemal v preteklosti, ali se je nedavno cepili oziroma to namerava, in anamnezo reakcij, povezanih z infuzijo
The “primary” statistical test for “response” was the trend test of CR versus PR versus non-response (p < 0.0001) Abbreviations: NA, not available; ORR: overall response rate; CR: complete response; PR: partial response 
Okrajšave: NA: ni na voljo; ORR: celokupni odgovor (overall response rate); CR: popolni odgovor
Neither age, sex, lymphoma grade, initial diagnosis, presence or absence of bulky disease, normal or high LDH nor presence of extranodal disease had a statistically significant effect (Fisher's exact test) on response to rituximab. 
Na odgovor na rituksimab naslednji dejavniki niso imeli statistično značilnega vpliva (Fisherjev natančni test): starost, spol, gradus limfoma, začetna diagnoza, prisotnost ali odsotnost obsežne bolezni, normalna ali visoka koncentracija LDH ali ekstranodalna bolezen.
Rixathon monotherapy is indicated for treatment of patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. 
Zdravilo Rixathon je indicirano za samostojno zdravljenje bolnikov s III. in IV. stadijem folikularnih limfomov, ki so neodzivni na kemoterapijo ali se je pri njih bolezen po kemoterapiji drugič ali že večkrat ponovila.
Since hypotension may occur during rituximab administration, consideration should be given to withholding anti-hypertensive medicinal product 12 hours prior to the Rixathon infusion. 
Ker se med aplikacijo rituksimaba lahko pojavi hipotenzija, je treba premisliti o tem, da bi 12 ur pred infuzijo zdravila Rixathon bolnik prenehal jemati zdravila proti visokemu krvnemu tlaku.
Toxic Epidermal Necrolysis (Lyell syndrome) and Stevens-Johnson syndrome, some with fatal outcome, have been reported very rarely. 
Zelo redko sta bila opisana toksična epidermalna nekroliza (Lyellov sindrom) ali Stevens-Johnsonov sindrom, v nekaterih primerih s smrtnim izidom.
• becoming very red in the face and other areas of the skin as a consequence of dilation of the blood vessels 
• močna zardelost obraza in drugih predelov kože zaradi razširjenja žil,
Initial treatment, bulky disease, weekly for 4 doses In pooled data from three trials, 39 patients with relapsed or chemoresistant, bulky disease (single lesion ≥ 10 cm in diameter), low grade or follicular B cell NHL received 375 mg/m2 of rituximab as intravenous infusion weekly for four doses. 
Začetno zdravljenje, obsežna bolezen, 4 odmerki, enkrat na teden Združeni podatki treh preskušanj navajajo, da je 39 bolnikov, pri katerih se je nizko maligni ali folikularni B-celični ne-Hodgkinov limfom ponovil ali pa so bili bolniki neodzivni na kemoterapijo in so imeli obsežno bolezen (ena lezija ≥ 10 cm v premeru), prejelo 4 odmerke po 375 mg/m2
Table 10a First-line treatment of chronic lymphocytic leukaemia Overview of efficacy results for rituximab plus FC vs. FC alone - 48.1 months median observation time 
Pregled rezultatov o učinkovitosti za rituksimab v kombinaciji s kemoterapijo FC v primerjavi s samo kemoterapijo FC - mediana opazovanja 48,1 meseca
• Rixathon will be given to you on the same day as your chemotherapy. 
ga boste dobili isti dan kot kemoterapijo.
Very rare cases of fatal progressive multifocal leukoencephalopathy (PML) have been reported following use of rituximab for the treatment of rheumatoid arthritis and autoimmune diseases including Systemic Lupus Erythematosus (SLE) and vasculitis. 
Pri uporabi rituksimaba za zdravljenje avtoimunskih bolezni so poročali o smrtnih primerih progresivne multifokalne levkoencefalopatije, in sicer pri revmatoidnem artritisu in avtoimunskih boleznih, za katere zdravilo ni odobreno, sistemskem eritematoznem lupusu (SLE) in vaskulitisu.
This is because Rixathon can affect the way some other medicines work. 
Zdravilo Rixathon namreč lahko vpliva na delovanje nekaterih drugih zdravil in obratno - tudi nekatera druga zdravila lahko vplivajo na delovanje zdravila Rixathon.
• you have severe heart failure or severe uncontrolled heart disease and have rheumatoid arthritis, 
• imate hudo srčno popuščanje ali hudo, neurejeno srčno bolezen in imate tudi revmatoidni artritis, granulomatozo s poliangiitisom, mikroskopski poliangiitis ali navadni pemfigus.
Only the highest frequency observed in the trials is reported 1 includes reactivation and primary infections; frequency based on R-FC regimen in relapsed/refractory CLL 2 see also section infection below 
1 Vključuje reaktivacijo in primarne okužbe; pogostnost temelji na režimu R-FC pri bolnikih s KLL, pri katerih se je bolezen ponovila, ali pri neodzivnih bolnikih.
Serum ickness-like reaction 
reakcija, podobna serumski bolezni
The antibody is produced by mammalian (Chinese hamster ovary) cell suspension culture and purified by affinity chromatography and ion exchange, including specific viral inactivation and removal procedures. 
in očiščeno z afinitetno kromatografijo ter ionsko izmenjavo, vključno s specifičnimi postopki inaktivacije in odstranjevanja virusov.
Lung infiltration 
infiltracija pljuč
Infusion-related reactions in the pemphigus vulgaris clinical study were common (58%). 
V klinični študiji pri navadnem pemfigusu so bile z infundiranjem povezane reakcije pogoste (58 %).
What Rixathon is and what it is used for What Rixathon is 
Kaj je zdravilo Rixathon in za kaj ga uporabljamo
Overall survival 
Celokupno preživetje (OS)
Table 15 Summary of efficacy by baseline autoantibody status Week 24 
Povzetek učinkovitosti glede na izhodiščno stanje protiteles
The recommended dose of Rixathon in combination with chemotherapy for induction treatment of previously untreated or relapsed/ refractory patients with follicular lymphoma is: 375 mg/m2 body surface area per cycle, for up to 8 cycles. 
Priporočeni odmerek zdravila Rixathon v kombinaciji s kemoterapijo za indukcijsko zdravljenje bolnikov s folikularnimi limfomi, ki se predhodno še niso zdravili ali se na prejšnje zdravljenje niso odzvali ali se jim je bolezen ponovila, je: 375 mg/m2 telesne površine na cikel do 8 ciklov.
c) If you are being treated for granulomatosis with polyangiitis or microscopic polyangiitis 
c) Če se zdravite zaradi granulomatoze s poliangiitisom ali mikroskopskega poliangiitisa
A maintenance infusion of 500 mg IV should be administered at months 12 and 18, and then every 6 months thereafter if needed, based on clinical evaluation. 
Vzdrževalno infuzijo 500 mg intravensko je treba uporabiti v 12. in 18. mesecu in nato vsakih
Table 11 Treatment of relapsed/refractory chronic lymphocytic leukaemia - overview of efficacy results for rituximab plus FC vs. FC alone (25.3 months median observation time) 
Zdravljenje kronične limfocitne levkemije pri bolnikih, pri katerih se je bolezen ponovila oziroma so bili neodzivni na zdravljenje - pregled rezultatov o učinkovitosti za rituksimab v kombinaciji s kemoterapijo FC v primerjavi s samo kemoterapijo FC (mediana opazovanja 25,3 meseca)
A total of 23/99 (23%) rituximab-treated patients from the induction of remission trial tested positive for ADA by 18 months. 
Do 18. meseca je imelo pozitiven izvid ADA skupno 23 od 99 (23 %) bolnikov, ki so bili v preskušanju zdravljeni z rituksimabom za indukcijo remisije.
Mean Cmax for serum rituximab following first infusion ranged from 157 to 171 μg/mL for 2 x 500 mg dose and ranged from 298 to 341 μg/mL for 2 x 1,000 mg dose. 
Povprečna serumska Cmax rituksimaba po prvi infuziji je bila 157 do 171 μg/ml za 2 x 500 mg odmerek ter 298 do 341 μg/ml za
The recommended dosage of Rixathon in combination with chemotherapy for previously untreated and relapsed/refractory patients is 375 mg/m2 body surface area administered on day 0 of the first treatment cycle followed by 500 mg/m2 body surface area administered on day 1 of each subsequent cycle for 6 cycles in total. 
Priporočeni odmerek zdravila Rixathon v kombinaciji s kemoterapijo pri bolnikih, ki predhodno še niso bili zdravljeni oziroma se na prejšnje zdravljenje niso odzvali ali pa se je bolezen pri njih ponovila, je 375 mg/m2 telesne površine, ki ga damo na dan 0 prvega cikla zdravljenja, v naslednjih ciklih zdravljenja pa dajemo 1. dan 500 mg/m2 telesne površine, skupaj 6 ciklov.
Do not breast-feed while you are being treated with Rixathon. 
Med zdravljenjem z zdravilom Rixathon ne smete dojiti.
Rixathon in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies. 
Zdravilo Rixathon je v kombinaciji z metotreksatom indicirano za zdravljenje odraslih bolnikov z zelo aktivnim revmatoidnim artritisom, ki niso zadostno odgovorili na druga imunomodulirajoča zdravila
Rituximab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. 
Rituksimab v kombinaciji z metotreksatom zmanjša hitrost napredovanja okvar sklepov, ki jih spremljamo z rentgenskim slikanjem, in izboljša funkcijsko zmogljivost.
Angina pectoris, atrial fibrillation, heart failure, myocardial infarction 
Srčne bolezni angina pektoris, atrijska fibrilacija,
There were no CTC Grade 4 IRRs and no deaths due to IRRs in the clinical trials. 
Reakcij stopnje 4 po lestvici skupnih kriterijev toksičnosti (CTC, Common Toxicity Criteria) in smrti zaradi reakcij v kliničnih preskušanjih ni bilo.
• feeling tired or dizzy 
• občutek utrujenosti ali omotičnosti,
Arthralgia / musculoskeletal pain, osteoarthritis, bursitis 
osteoartroza, burzitis
Rixathon in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. 
Zdravilo Rixathon je v kombinaciji s kemoterapijo indicirano za zdravljenje bolnikov s kronično limfocitno levkemijo, ki predhodno še niso bili zdravljeni oziroma se na prejšnje zdravljenje niso odzvali ali pa se je bolezen pri njih ponovila.
A total of 197 patients aged 15 years or older with severely, active granulomatosis with polyangiitis (75%) and microscopic polyangiitis (24%) were enrolled and treated in an active-comparator, randomised, double-blind, multicenter, non-inferiority trial. 
V randomiziranem, dvojno slepem, s placebom kontroliranem multicentričnem preskušanju neinferiornosti z aktivnim primerjalnim zdravilom so vključili in v njej zdravili skupno 197 bolnikov, starih 15 let ali več s hudo, aktivno granulomatozo s poliangiitisom (75 %) in mikroskopskim poliangiitisom (24 %).
In the maintenance therapy clinical trial, 30/57 (53%) patients in the rituximab arm experienced infections. 
V kliničnem preskušanju vzdrževalnega zdravljenja so se okužbe v skupini z rituksimabom pojavile pri 30 od 57 (53 %) bolnikov.
Subsequent doses of Rixathon can be infused at an initial rate of 100 mg/h, and increased by 100 mg/h increments at 30 minute intervals, to a maximum of 400 mg/h. 
Nadaljnje odmerke zdravila Rixathon lahko dajemo z začetno hitrostjo 100 mg/h, ki jo lahko vsakih
d) If you are being treated for granulomatosis with polyangiitis or microscopic polyangiitis 
d) Če se zdravite zaradi granulomatoze s poliangiitisom ali mikroskopskega poliangiitisa
Minor relapses (not life threatening and not involving major organ damage) occurred in seven patients in the rituximab group (12%) and eight patients in the azathioprine group (14%). 
Blažji recidivi (takšni, ki niso bili življenjsko ogrožajoči in niso vključevali okvare pomembnega organa) so se pojavili pri sedmih bolnikih v skupini z rituksimabom
Log-rank p value 
Vrednost p v testu log rank
It is recommended that immunoglobulin levels are determined prior to initiating treatment with Rixathon. 
Pred začetkom zdravljenja z zdravilom Rixathon je priporočljivo določiti koncentracije imunoglobulinov.
During rituximab maintenance treatment for up to 2 years, leucopenia (5% vs. 2%, grade 3/4) and neutropenia (10% vs. 4%, grade 3/4) were reported at a higher incidence when compared to observation. 
Incidenca levkopenije in nevtropenije 3. ali 4. stopnje sta bili v skupini, ki je prejemala vzdrževalno zdravljenje z rituksimabom do 2 leti, višja (levkopenija: 5 %, nevtropenija: 10 %) kot v opazovani skupini (levkopenija: 2 %, nevtropenija: 4 %).
Patients treated with Rixathon may receive non-live vaccinations. 
Bolniki, ki se zdravijo z zdravilom Rixathon, lahko prejmejo mrtva cepiva, vendar je lahko odgovor nanje zmanjšan.
What you need to know before you are given Rixathon Do not take Rixathon if 
Kaj morate vedeti, preden boste dobili zdravilo Rixathon
p < 0.0001 
mediana TTP: p < 0,0001
The chemotherapy should be given after Rixathon infusion. 
Kemoterapijo dajemo po infuziji zdravila Rixathon.
Rheumatoid arthritis only 
Samo revmatoidni artritis
• memory loss, trouble thinking, difficulty walking or sight loss -these may be due to a very rare, 
• poslabšanje spomina, motnje mišljenja, težave s hojo ali izguba vida - lahko so posledica zelo redke, resne okužbe možganov, ki je včasih smrtna (imenujemo jo progresivna multifokalna levkoencefalopatija ali PML).
Other serious ADRs reported include hepatitis B reactivation and PML (see section 4.4.) 
Med drugimi resnimi neželenimi učinki so poročali tudi o reaktivaciji virusa hepatitisa B in o PML
The most frequent ADRs following receipt of rituximab in clinical studies were IRRs (refer to Table 2). 
Najpogostejši neželeni učinki po prejemu rituksimaba v kliničnih preskušanjih so bile reakcije,
Blood and lymphatic system disorders 
Bolezni krvi in limfatičnega sistema nevtropenija1
• severe skin problems causing blisters that can be life-threatening. 
• okvara črevesne stene (predrtje), • hude težave s kožo, ki povzročijo mehurje in so lahko smrtno nevarne.
Prophylaxis with adequate hydration and administration of uricostatics starting 48 hours prior to start of therapy is recommended for CLL patients to reduce the risk of tumour lysis syndrome. 
Za zmanjšanje tveganja za sindrom lize tumorja je za bolnike s KLL priporočljiva profilaksa s primerno hidracijo in dajanjem urikostatika, ki ga začnemo dajati 48 ur pred pričetkom zdravljenja.
B cell levels in human neonates following maternal exposure to rituximab have not been studied in clinical trials. 
V kliničnih preskušanjih niso proučevali števila celic B pri novorojenčkih mater, zdravljenih z rituksimabom.
It sticks to the surface of a type of white blood cell called “B-Lymphocyte”. 
Veže se na površino vrste belih krvnih celic, limfocitov B. Ko se rituksimab veže na površino teh celic, povzroči njihovo smrt.
Mean change from baseline: Modified total sharp score Erosion score Joint space narrowing score Proportion of patients with no radiographic change 
Ocena zožitve sklepne špranje Delež bolnikov brez radioloških sprememb
Due to the long retention time of rituximab in B cell depleted patients, women of childbearing potential should use effective contraceptive methods during and for 12 months following treatment with Rixathon. 
Zato morajo ženske v rodni dobi med zdravljenjem z zdravilom Rixathon in še 12 mesecev po njem uporabljati učinkovita kontracepcijska sredstva.
Bronchitis, sinusitis, gastroenteritis, tinea pedis 
Infekcijske in parazitske bolezni okužba zgornjih dihal, okužbe sečil bronhitis, sinuzitis, gastroenteritis, tinea pedis
Figure 3: 
Preglednica 3.
Rixathon is used for the treatment of rheumatoid arthritis. 
Zdravilo Rixathon uporabljamo za zdravljenje revmatoidnega artritisa, ki je bolezen sklepov.
• indigestion 
• omotičnost,
• severe vision loss 
• hudo poslabšanje vida.
ESR 
ORR
Progression-free survival (PFS) Overall survival 
PFS: preživetje brez napredovanja bolezni (Progression-Free Survival)
Dizziness may occur following administration of rituximab (see section 4.8). 
Po dajanju rituksimaba se lahko pojavi omotica (glejte poglavje 4.8).
Rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis, and pemphigus vulgaris 
Revmatoidni artritis, granulomatoza s poliangiitisom, mikroskopski poliangiitis in navadni pemfigus
Clinical experience in Non-Hodgkin's lymphoma and in chronic lymphocytic leukaemia 
Klinične izkušnje pri ne-Hodgkinovem limfomu in kronični limfocitni levkemiji
Re-treatment 
Zdravilo
† Outcome at 24 weeks Significant difference from placebo + MTX at the primary timepoint: ***p ≤ 0.0001 
Značilna razlika v primerjavi s placebom ob času primarnega cilja študije: *p < 0,05; **p < 0,001; ***p ≤ 0,0001
What Rixathon is used for 
Za kaj uporabljamo zdravilo Rixathon